The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2018 | Novel therapies for the treatment of NSCLC: immunotherapy and targeted agents
In this interview, Federico Cappuzzo, MD, PhD, of AUSL della Romagna, Ravenna, Italy, discusses novel therapies for the treatment of non-small cell lung cancer (NSCLC) from the 2018 European Lung Cancer Congress (ELCC) in Geneva, Switzerland. Dr Cappuzzo focuses on immunotherapy and targeted agents, and emphasizes the continued importance of defining the biological characteristics of NSCLC, particularly PD-L1 expression.
